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A B S T R A C T
The oxidative phosphorylation system is important for adipocyte differentiation. Therefore, xenobiotics in-
hibitors of the oxidative phosphorylation system could affect adipocyte differentiation and adipokine secretion.
As adipokines impact the overall health status, these xenobiotics may have wide effects on human health. Some
of these xenobiotics are widely used therapeutic drugs, such as ribosomal antibiotics. Because of its similarity to
the bacterial one, mitochondrial translation system is an off-target for these compounds. To study the influence
of the ribosomal antibiotic linezolid on adipokine production, we analyzed its effects on adipocyte secretome.
Linezolid, at therapeutic concentrations, modifies the levels of apolipoprotein E and several adipokines and
proteins related with the extracellular matrix. This antibiotic also alters the global methylation status of human
adipose tissue-derived stem cells and, therefore, its effects are not limited to the exposure period. Besides their
consequences on other tissues, xenobiotics acting on the adipocyte oxidative phosphorylation system alter
apolipoprotein E and adipokine production, secondarily contributing to their systemic effects.
1. Introduction
The oxidative phosphorylation system (OXPHOS) includes the
electron transport chain (ETC) respiratory complexes I to IV (CI-CIV)
and the ATP synthase (complex V, CV). Several OXPHOS subunits are
encoded in the mitochondrial DNA (mtDNA). This molecule also codes
for 2 ribosomal (rRNAs) and 22 transfer (tRNAs) RNAs needed for the
expression of the 13 mtDNA-encoded polypeptides. Mature cells require
OXPHOS function to perform many of their activities but it is also im-
portant for cell differentiation.
Genetic manipulation of the OXPHOS system affects adipocyte dif-
ferentiation. This manipulation appears to be accompanied by a defect
in adipokine secretion. Thus, it has been reported that a mutated thy-
midine kinase 2 (TK2) knock-in mouse showed mtDNA depletion in
white adipose tissue and reduced fat accumulation. There was also a
severe reduction in leptin mRNA and circulating protein levels [1].
Mouse 3T3-L1 cells knocked down for the mitochondrial transcription
factor A (TFAM) showed a decrease in mtDNA copy number, levels of
ETC subunits, CI and CIV activities, and oxygen consumption. These
cells also showed a diminished adiponectin expression at both gene and
secreted protein levels [2]. Adiponectin mRNA expression was also
decreased in TFAM knocked down human mesenchymal stem cells
(hMSCs) [3]. Mouse 3T3-L1 or adipose tissue derived stem (mASCs)
cells that lacked the CR6/gadd45-interacting protein Gadd45gip1/
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Crif1, a translation/assembly factor for mtDNA-encoded polypeptides,
expressed lower levels of mtDNA-encoded subunits and displayed dis-
rupted adipocyte differentiation, accompanied by a reduced adipo-
nectin expression [4].
Physiologic manipulation of OXPHOS can also affect adipokine se-
cretion. Oxygen is the ultimate electron acceptor in the ETC and hy-
poxia restrained adipogenic differentiation in both mouse pre-
adipocytes and hMSCs [3,5]. It has been found that adiponectin and
leptin release was increased and decreased, respectively, in human
adipocytes differentiated at 10% oxygen compared with 21% [6].
We have previously shown that some OXPHOS xenobiotics could
alter the adipocyte differentiation of human adipose tissue-derived stem
cells (hASCs) [7]. In addition to genetic and physiologic intervention,
chemical manipulation of OXPHOS can also affect adipokine secretion.
It was found that CI inhibitor rotenone decreased adiponectin secretion
of rat adipocytes and adiponectin mRNA expression in hMSCs [3,8].
Capsaicin, another CI inhibitor, decreased leptin and increased adipo-
nectin expression in 3T3-L1 adipocytes [9]. The CIII inhibitor antimycin
A reduced adiponectin mRNA levels in mouse 3T3-L1 cells [10]. The CV
inhibitor oligomycin diminished adiponectin mRNA levels and secreted
adiponectin in mouse 3T3-L1 cells [2,10].
Some OXPHOS xenobiotics are widely used therapeutic drugs. For
example, nucleoside reverse transcriptase inhibitors (NRTIs) are used
against the human immunodeficiency virus (HIV), the agent causing the
acquired immune deficiency syndrome (AIDS). However, these drugs
can also inhibit the DNA polymerase gamma (POLG), the enzyme re-
quired for mtDNA replication. Thus, OXPHOS function was reported as
a common target of NRTI toxicity [11]. NRTIs reduced adipocyte dif-
ferentiation and leptin secretion by hASCs-derived adipocytes [7]. They
also decreased adiponectin mRNA expression and protein secretion in
mouse 3T3-L1 and 3T3-F442A cells and in primary human sub-
cutaneous preadipocytes [12–14]. Systemic adiponectin levels were
also reduced in patients under antiretroviral therapy [15]. The ribo-
somal antibiotic linezolid (LIN) is considered a promising option in the
treatment of multidrug resistant tuberculosis [16]. Unfortunately, side
effects, such as myelosuppression, lactic acidosis and optical and per-
ipheral neuropathy have been associated to this antibiotic [16]. At
concentrations below the steady-state peak serum concentration [17],
LIN inhibited hASCs mitochondrial protein synthesis and decreased the
triglycerides (TGs) amount and secreted leptin in hASCs-derived adi-
pocytes [7].
Adipokines modulate many metabolic pathways and have a broad
range of systemic actions [18]. The previous observations indicated that
an OXPHOS blockage modifies the secretion of some adipokines. Then,
an adipocyte OXPHOS disruption caused by off-target effects of ther-
apeutic drugs might affect people health status. Therefore, we analyzed
the effect of LIN on adipocyte secretome to uncover factors whose se-
cretion was altered.
2. Materials and methods
2.1. Chemicals
All reagents used were of research or cell culture quality.
Chloramphenicol (CAM) and LIN were purchased from Sigma-Aldrich
(St Louis, MO, USA).
2.2. Cells, growth and differentiation conditions
StemPro® Human Adipose-Derived Stem Cells (#R7788-115,
Gibco™, Thermo Fischer Scientific) derive from human adipose tissue
collected during liposuction procedures and were cryopreserved at
passage 1 from primary cultures. Each lot of hASCs originates from a
single donor of human lipoaspirate tissue, and the two previously
characterized lots used here [7], are named hASCs-1 and hASCs-2. In
some experiments, we used hASCs derived from 13 different donors,
after a signed informed consent was obtained [19].
These cells were generally grown in MesenPRO RS™ medium
(Gibco™, Thermo Fischer Scientific), containing 5 mM glucose and 2%
fetal bovine serum (FBS) complemented with MesenPRO RS™ growth
supplement and 2 mM L-glutamine prior to use. To avoid undesired
phenotypic effects, cells were grown in the absence of antibiotics [20].
To induce adipogenic differentiation, confluent hASCs were in-
cubated for 21 days with StemPro® Adipogenesis Differentiation Kit
(Gibco™), as previously described [7].
2.3. Analysis of adipocyte differentiation
Intracellular lipids were stained with the hydrophilic stain Nile Red
that, when partitioned in a hydrophobic environment, becomes fluor-
escent. For quantitative determination of Nile Red fluorescence, the
NovoStar MBG Labtech microplate instrument was used (Ex: 485 nm /
Em: 572 nm).
Adipogenesis Detection Kit (Abcam) was used to quantify TGs ac-
cumulation in cells according to the manufacturer's instructions. In this
assay, TGs are solubilized and hydrolyzed to glycerol, which is subse-
quently oxidized to convert the probe to generate color (λmax =
570 nm). A NovoStar MBG Labtech microplate instrument was used for
measurements.
For quantitative determination of adiponectin and leptin in cell
culture supernatants, Human Adiponectin ELISA kit (Millipore) and
Leptin Human ELISA Kit (Abcam) were used [7], according to the
manufacturer's instructions.
For immunocytochemistry, the cultured cells were fixed with 4%
paraformaldehyde for 15 min at room temperature and permeabilized
with 0.1% Triton X-100 for 10 min. After blocking with 0.1% bovine
serum albumin (BSA), the washed cells were incubated for 1 h at room
temperature with a primary antibody against APOE (Abcam).
Subsequently, the cells were incubated with fluorescence-labeled sec-
ondary Alexa Fluor® 594 (Molecular Probes) at room temperature for
30 min, protected from light. The cells were further incubated with
1 μM 4′,6-diamidino-2-phenylindole (DAPI) for nuclear staining.
Between incubations, samples were washed with phosphate buffered
saline (PBS) containing 0.05% Tween.
2.4. Analysis of mitochondrial function
The enzymatic activity of citrate synthase (CS) was assayed fol-
lowing previously described protocols [21]. Protein concentration was
determined by the Bradford protocol (#500-0006; Bio-Rad) [22]. CIV
activity and levels were determined using the Complex IV Human
Specific Activity Microplate Assay Kit (Mitosciences, Abcam®) ac-
cording to the manufacturer's instructions.
2.5. Genetics characterization and gene expression analysis
APOE genotyping was performed by polymerase chain reaction
(PCR) amplification and sequencing using primers and conditions de-
scribed elsewhere [23,24]. These sequences were obtained using the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applera Rockville, MD,
USA) and an ABI Prism 3730xl DNA analyzer (Applied Biosystems,
Foster City, CA, USA).
For quantitative determination of the percentage of 5-methylcyto-
sine (5-mC) in hASCs genome, the MethylFlash™ Methylated DNA
Quantification Kit (Epigentek) was used, following the manufacturer's
instructions.
To assess the methylation levels of the APOE gene, bisulfite con-
version of genomic DNA (500 ng each) was carried out using the EZ
DNA Methylation™ Kit (Zymo Research) according to the manufac-
turer's protocol. PCR was carried out with 100 ng of bisulfite-converted
DNA, using the Pyromark PCR Kit (Qiagen) and the primers described
elsewhere [25]. PCR products were purified using streptavidin-coated
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sepharose beads to capture the biotin-labeled primer. Pyrosequencing
was carried out on a PyroMark Q96 ID (Qiagen).
To assess mRNA levels, total RNA was isolated from exponentially
growing or differentiated cells using a NucleoSpin® RNA II kit
(Macherey-Nagel) according to the manufacturer's protocol. Total RNA
(1 μg) was reversed-transcribed (RT) with the Transcriptor First Strand
cDNA Synthesis Kit (Roche), using the manufacturer's conditions. The
level of APOE mRNA was determined by quantitative RT-PCR (RT-
qPCR) using the One-Step Real-Time system (Applied Biosytems). The
expression levels were normalized using the 18 S rRNA. The ΔCt
method was used to calculate fold expression. StepOne software version
2.0 (Applied Biosystems) was used for data analysis.
2.6. Secretome analysis
Minimum media (without FBS) was collected after 48 h in contact
with the cells, and then centrifuged and filtered. Protein precipitation
was performed following the traditional protocol using cold acetone
[26].
Aliquots were resolubilized in 0.5 M triethylammonium bicarbonate
buffer (TEAB), and 50 µg of each sample was digested and labeled with
iTRAQ™ labeling reagents following manufacturer's instructions (AB
SCIEX, Foster City, CA) and as described in detail previously [27]. After
labeling, samples were combined and concentrated under vacuum and
resuspended in 0.1% ammonium formate/2% acetonitrile for tandem
mass spectrometry (MS). Samples were analyzed by nano-liquid chro-
matography (EASY-nLC 1000, Proxeon, Thermo Scientific) coupled
with an ion trap mass spectrometer (LTQ Orbitrap Velos, ThermoFisher
Fig. 1. Linezolid effect on OXPHOS complexes. A) hASCs mitochondrial protein levels. Immunoblot images for different mitochondrial proteins. B) Levels of hASCs OXPHOS complexes.
Image of a BN/SDS-PAGE gel. C) Adipocyte mitochondrial protein synthesis. Representative image of gels showing the electrophoretic patterns of mitochondrial translation products
(right panel) and loading control (left panel). M, U, D, - and + code for molecular weight marker, undifferentiated and adipocyte-differentiated hASCs and 30 μM linezolid unexposed or
exposed, respectively.
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Scientific), following protocols described elsewhere [28]. MS/MS data
were processed using Protein Pilot v.4.5 software (AB SCIEX). The
confidence interval for protein identification was set to ≥ 95%
(p<0.05). Only peptides with an individual ion score above the 1%
False Discovery Rates (FDR) threshold were considered correctly
identified. Only proteins having at least two quantifiable peptides were
considered in the quantization.
For peptide mass fingerprinting, a 4800 Plus Proteomics Analyzer
MALDI-TOF/TOF (Applied Biosystems) was used. Raw data file con-
version tools generated mgf files, which were also searched against the
human database using the Mascot Server v. 2.3.02 (AB SCIEX).
Lactate dehydrogenase (LDH) activity was determined using the
commercial Lactate Dehydrogenase Colorimetric Assay Kit (Abcam®),
according to the manufacturer's instructions.
2.7. Protein amount assessment by Western blot
Secreted proteins were concentrated using Amicon® Ultra-15 and
Ultra-0.5 Centrifugal Filters (Millipore). Cells were lysed in RIPA buffer
(Tris-HCl 50 mM pH = 7.4, NaCl 50 mM, sodium deoxycholate 0.5%,
ethylenediaminetetraacetic acid (EDTA) 5 mM, Triton X-100 1%, pro-
tease inhibitor 1X). For Western blots, primary antibodies were against
p.MT-CO1 (1:1000, 459600, Invitrogen™), SDHA (1:5000, 459200,
Invitrogen™), Actin (1:2000, A2066, Sigma), APOE (1:1000, ab1906,
Abcam), FN1 (1:400, ab2413, Abcam) and OXPHOS human WB anti-
body cocktail (Abcam, ab110411). Primary antibodies against TIM21,
MRPL45, NDUFA9, p.MT-CO1, p.MT-CO2, COX4-1 and ATP5B were
raised in rabbit. These antigen-antibody complexes were detected by
horseradish peroxidase (HRP)-coupled secondary antibodies and en-
hanced chemiluminescence on X-ray films. For blue native-poly-
acrylamide gel electrophoresis (BN-PAGE), mitochondria were solubi-
lized in buffer (1% digitonin, 20 mM Tris-HCl, pH 7.4, 0.1 mM EDTA,
50 mM NaCl, 10% (w/v) glycerol, and 1 mM phenylmethylsulfonyl
fluoride) to a final concentration of 2 mg/ml for 30 min at 4 °C. Lysates
were cleared by centrifugation (20,000×g, 15 min, 4 °C) before addi-
tion of 10X loading dye (5% Coomassie brilliant blue G-250, 500 mM 6-
aminohexanoic acid, and 100 mM Bis-Tris, pH 7.0) and separated on
4–14% polyacrylamide gradient gels as described [29].
2.8. Statistics
The statistical package StatView 6.0 was used to perform all the
statistics. Data for mean and standard deviation are presented. The
Kolmogorov–Smirnov test was used to check the normal distribution.
The unpaired two-tailed t-test was used to compare parameters. P va-
lues lower than 0.05 were considered statistically significant.
3. Results
3.1. Differences between human adipose tissue-derived stem cell and
adipocyte secretomes
In this study, we used hASCs from two different individuals (hASCs-
1 and 2). Both proliferative and differentiating hASCs were simulta-
neously cultured. After three weeks growing in differentiation media,
approximately half of the hASCs showed adipogenic conversion [7].
Then, proliferation and differentiation media were removed and both
cell cultures, hASCs and adipocytes, were 3-times washed with PBS and
incubated for 2 additional days in a serum-free Dulbecco's modified
Eagle's medium (DMEM) synthetic media. The secretome analysis dis-
played differences in the concentration of 31 proteins between media
from proliferative and differentiated cells (Table S1). Eight of them
were found different in only one of the differentiation processes
(hASCs-1 or 2), while 23 were found different in both of them (hASCs-1
and 2).
Besides of secreted proteins, these media could contain leaked
proteins. To rule out cell lysis, we determined the cytosolic enzyme
activity LDH in the culture medium and normalized it by the number of
cells. This activity was compared to that of a positive control obtained
by cell lysis (freeze-thawing). Normalized LDH activity was only a small
percentage [12.1%±6.1 (8), P< 0.0001] of that from the positive
control [100%±3.1 (3)], meaning that very low cell lysis occurred
during the 2 days culture period. On the other hand, keratins are
usually considered contaminants coming from users’ skin, hair and nails
[30]. Moreover, according to the human protein reference database
(HPRD, http://www.hprd.org/), of all these proteins, only keratins and
fatty acid-binding protein 4 (FABP4) lacked the secretory signal pep-
tide. However, FABP4 is secreted through a non-classical pathway [31].
Excepting keratins, all these proteins had been previously reported in
other studies on adipocyte secretomes [32]. Therefore, all these results
suggested that these proteins were truly differentially secreted by adi-
pocytes.
During adipocyte differentiation, secretion of 21 and 10 of these
proteins was down and up regulated, respectively. Most of them were
related with the extracellular matrix. Surprisingly, we did not find
adiponectin and leptin in the secretome analysis despite that, using
enzyme-linked immunosorbent assay (ELISA), we had previously ob-
served a 4- and 6-times increase, respectively, in their culture medium
levels [7]. However, leptin is mainly detected with antibody-based
methods and its absence is not a rare observation for this kind of ana-
lysis [33].
3.2. Linezolid modifies the adipocyte secretome
LIN is a ribosomal antibiotic initially developed to treat Gram-po-
sitive bacterial infections. Moreover, the latest World Health
Organization (WHO) guidelines have included linezolid in the list of
core second line agents to treat multidrug resistant tuberculosis [16].
The LIN dose used in clinical practice is 600 mg every 12 h. The steady-
state peak serum concentrations (44.5–80.0 μM) are reached 0.5–2 h
after oral administration [17].
We had previously observed that 30 μM LIN decreased hASCs mi-
tochondrial protein synthesis [7]. mtDNA only codes OXPHOS poly-
peptides. To confirm the LIN effect on OXPHOS function, we studied the
steady-state levels of different hASCs nuclear DNA (nDNA)- and
mtDNA-encoded proteins. LIN (30 μM and 90 μM) does not alter the
levels of nDNA-encoded ATP5B (a CV subunit), MRPL45 (a mitochon-
drial ribosomal protein) and TIM21 (a presequence translocase subunit
from the mitochondrial inner membrane) mitochondrial proteins
(Fig. 1A). However, these LIN concentrations decrease the levels of ETC
complexes subunits [Complex I (CI)- NDUFA9; Complex IV (CIV)- p.MT-
CO1, 2 and COX4-1], despite some of them (NDUFA9 and COX4-1) are
nDNA-encoded proteins (Fig. 1A). As mtDNA-encoded polypeptides are
Fig. 2. Levels of different adipocyte differentiation parameters in 30 μM linezolid-treated
cells. Dashed line (100%) represents the mean values for untreated cells. The bars in-
dicate the percentage of the different adipocyte variables. Error bars represent the stan-
dard deviation. *, P ≤ 0.0002 (versus untreated cells).
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important for complexes assembly [34], a reduction in their levels
could secondarily decrease nDNA-encoded ETC proteins. Interestingly,
a two-dimension electrophoresis of samples from 90 μM LIN-treated
hASCs (BN/SDS-PAGE) showed CI and CIV vanishing and that ATP5B
was mainly associated to CV sub-complexes (Fig. 1B). These sub-com-
plexes usually appear when mtDNA-encoded p.MT-ATP6 or 8 subunit
levels are very low [35]. 30 μM LIN also decreases mitochondrial pro-
tein synthesis in hASC-derived adipocytes (Fig. 1C). Thus, the LIN in-
hibition of mitochondrial translation is responsible for the reduction in
adipocyte CIV activity and quantity [7].
This effect on mitochondrial parameters was accompanied by a re-
duction in adipocyte TGs and secreted leptin [7]. These studies were
performed in two different hASCs obtained from a commercial com-
pany (no phenotypic information is provided by the company). To
avoid potential biases from unknown donors, we extended our analysis
to encompass 11 other hASCs from known donors (Table S2). We ver-
ified that 30 μM LIN significantly decreased Nile Red lipophilic
staining, intracellular TGs levels and secreted leptin (Fig. 2).
The culture in the presence of 0, 30 or 60 μM LIN changed the
concentration of 13 proteins, including 4 keratins, in only one of the
adipocyte differentiation processes (Table S3). For 5 and 8 proteins, LIN
decreased and increased, respectively, their secretion. Four of them,
FABP4, apolipoprotein E (APOE), plasminogen activator inhibitor 1
(PAI-1) and complement factor D (adipsin) were not related with
Fig. 3. Linezolid effect on secreted fibronectin (FN1) and apolipoprotein E (APOE) levels. A) Protein loading control. Image of a SDS-PAGE gel for adipocyte-differentiated human adipose
tissue-derived stem cells (hASCs) secretome samples after Coomassie blue staining. B) FN1 levels. Immunoblot image from adipocyte-differentiated hASCs exposed to different linezolid
concentrations. C) Graph representing fibronectin relative quantity. D) APOE levels. Immunoblot image from adipocyte-differentiated hASCs exposed to different linezolid concentrations.
As we were particularly interested in the APOE protein, and it had been reported that the specificity of many antibodies to its target protein is very low [63], we verified its specificity by
performing peptide mass fingerprinting of the band obtained from the Western blot analysis of the culture medium. APOE was one of the two detected proteins in this band (Table S4). E).
Graph representing APOE quantity. M, U, D, DL30 and DL60 code for molecular weight marker, undifferentiated hASCs, 0, 30 and 60 μM linezolid-exposed adipocyte-differentiated
hASCs, respectively. Dashed line (100%) represents the mean values for linezolid-untreated adipocyte differentiated hASCs. The bars indicate the protein percentage of the un-
differentiated and linezolid-treated adipocyte-differentiated hASCs. Error bars represent the standard deviation. *, P ≤ 0.0433 (versus linezolid-untreated adipocyte differentiated
hASCs). #, P = 001 (versus 30 μM linezolid-treated adipocyte-differentiated hASCs).
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cytoskeleton or extracellular matrix. FABP4 and APOE levels rose along
differentiation, but LIN softened this increase. Adipsin amount elevated
during differentiation and LIN potentiated this upsurge. PAI-1 quantity
decreased in the adipocyte differentiation, but LIN tempered this drop.
At 60 μM LIN, the difference in secretion was close to be significant in
both adipocyte differentiation processes for two proteins, Fibronectin
(FN1) and APOE. To confirm this result, we analyzed these FN1 and
APOE proteins by Western blot. There was a significant decrease in
secreted FN1 levels after adipocyte differentiation. This reduction was a
little mitigated when differentiation was performed in the presence of
30 or 60 μM LIN (Fig. 3A-C). On the other hand, there was not signal for
APOE protein in hASCs. 30 or 60 μM LIN significantly diminished the
increase in secreted APOE levels after adipocyte differentiation
(Fig. 3A, D, E).
3.3. Linezolid alters global DNA methylation
Next, we determined APOE levels in cell homogenates. APOE pro-
tein was found in adipocytes but it was not present in hASCs (Fig. 4A).
LIN (30 and 60 μM)-treated adipocytes showed lower APOE amount.
Fig. 4. Linezolid effect on intracellular apolipoprotein E (APOE) levels. A) APOE levels. Immunoblot image from adipocyte-differentiated human adipose tissue-derived stem cells (hASCs)
exposed to different linezolid concentrations. Actin levels are used as a loading control. B) Immunofluorescent staining of adipocyte-differentiated hASCs. Representative image of an
APOE immunocytochemical analysis. C) APOE levels of adipocyte-differentiated hASCs treated with ribosomal antibiotics. Representative images of immunoblots for APOE and actin. D)
Graph representing APOE quantity. DC2.5 codes for 2.5 μM cloramphenicol-exposed adipocyte-differentiated hASCs. M, U, D, DL30, DL60 and DL90 code for molecular weight marker,
undifferentiated hASCs, 0, 30, 60 and 90 μM linezolid-exposed adipocyte-differentiated hASCs, respectively. Dashed line (100%) represents the mean values for adipocyte-differentiated
hASCs. The bars indicate the APOE percentage of the chloramphenicol or linezolid-treated adipocyte-differentiated hASCs. Error bars represent the standard deviation. *, P = 0.0273
(versus untreated-adipocyte differentiated hASCs).
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Immunocytochemical analysis of cells treated with 90 μM LIN con-
firmed the effect of this antibiotic on intracellular APOE quantity
(Fig. 4B). Other mitochondrial translation inhibitor, CAM, at con-
centration (2.5 μM) well below the lower limit of its therapeutic range
(46.4–92.8 μM) [36], decreased adipocyte TGs and secreted leptin [7].
This drug also tends to decrease APOE protein levels (Fig. 4C, D).
To determine the reasons for this decrease in cell APOE levels, we
measured APOE mRNA expression by RT-qPCR. The mRNA levels were
decreased in 90 μM LIN-treated adipocytes (Fig. 5A, B). APOE gene
contains a CpG island (CGI) with transcriptional enhancer/silencer
activity in exon 4. APOE2 and APOE4 alleles reduce and increase, re-
spectively, one CpG dinucleotide when compared with APOE3 allele.
Therefore, the APOE allele could alter the methylation landscape and
the gene transcription [25]. The hASCs-1 and hASCs-2 genotypes were
APOE3/4 and APOE3/3, respectively (Fig. 5C). These are the most
frequent genotypes in the Spanish population (16.5% and 72.0%, re-
spectively) [24], and are also the most common almost everywhere
[37]. We determined this CGI methylation state. We did not find dif-
ferences in methylation levels of 2 different regions from APOE exon 4
among hASCs and adipocytes or among LIN-treated and untreated
adipocytes (Fig. 5D).
It has been published that 5-aza-2′-deoxycytidine (5azadC), a re-
agent having inhibitory effects on DNA methyltransferase, reduced
adipocyte differentiation of mouse 3T3-L1 cells [38] and hMSCs [39].
To check if LIN effect on adipocyte differentiation is mediated through
nDNA methylation, we analyzed this variable in unexposed or LIN-ex-
posed adipocytes differentiated hASCs. Adipocyte differentiation pro-
voked a significant increase in global nDNA methylation (Fig. 6A).
However, this increase was avoided when cells were treated with 90 μM
LIN.
It was reported that 5azadC decreased peroxisome proliferator-ac-
tivated receptor gamma (PPARγ) expression, an important factor for
adipocyte differentiation [39,40]. It has been recently found that NRTIs
altered nDNA methylation [41], and downregulated PPARγ and
mtDNA-encoded genes expression [42]. Moreover, ethidium bromide, a
DNA intercalating agent that provokes mtDNA depletion, reduced 3T3-
L1MT-CO1 and PPARγmRNA levels [4]. To confirm an effect on PPARγ
expression of OXPHOS xenobiotics, we determined the PPARγ mRNA
level after LIN exposure and observed that LIN (90 μM) significantly
decreased PPARγ mRNA amount (Fig. 6B).
The LIN toxicity limits the treatment time to 28 days, the Food and
Drug Administration (FDA)-approved maximum duration [16]. Thus,
the differentiation of LIN-exposed adipocytes during this period could
be altered. Fortunately, most toxic effects are reversible and corrected
by discontinuing LIN therapy [16]. However, as LIN exposure during
differentiation affects nDNA methylation, to know if LIN might have a
future effect on hASCs differentiation to adipocyte, we looked for po-
tential hASCs epigenetic effects and analyzed the global nDNA methy-
lation. Thus, this process was also diminished in 90 μM LIN-treated
hASCs (Fig. 7A). Interestingly, when hASCs were treated with 30 μM
Fig. 5. Apolipoprotein E (APOE) expression. A) Representative image of a RT-qPCR result. B) Graph representing APOE mRNA levels, normalized using the 18S rRNA, in adipocyte-
differentiated human adipose tissue-derived stem cells (hASCs). C) APOE genotype. D) APOE gene CGI methylation. U, D, DL30 and DL90 code for undifferentiated hASCs, 0, 30 and
90 μM linezolid-treated adipocyte-differentiated hASCs, respectively. *, P = 0.0322 (versus untreated-adipocyte differentiated hASCs).
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LIN for 10 days and then differentiated in the absence of LIN, they were
able to recover CIV activity and quantity but adipocyte differentiation
was affected and Nile Red staining and secreted leptin was diminished
(Fig. 7B, C).
4. Discussion
The number and set of differentially secreted proteins between
preadipocytes and adipocytes varies in the different reports on adipo-
cyte secretomes, despite a large percentage of cells differentiate to
adipocytes in all of them. Maybe the species from which the cell type
was obtained, the cell type, differentiation protocol and method of
analysis are responsible for these large variations. However, some
proteins are frequently found in many of these reports [32]. Thus, some
of them are related with remodeling of the extracellular matrix, a
crucial event during adipocyte differentiation, in which cell mor-
phology converts from a fibroblast-like to a spherical shape [43], and
some others are adipokines, a variety of circulating factors, which
regulate systemic metabolism.
We had previously observed that LIN, an inhibitor of the mi-
tochondrial protein synthesis, was able to decrease adipocyte differ-
entiation and leptin secretion [7]. Here, we report a contrary effect of
LIN on secreted APOE and FN1 protein levels. LIN also affects some
adipokines, such as FABP4, PAI-1 and Adipsin.
The amount of FN1 protein decreases during adipocyte differ-
entiation but LIN tends to mitigate this decline. The effect on FN1 se-
cretion is different in other cells with OXPHOS dysfunction. Thus, levels
of this protein were decreased in the extracellular space of rho0
(without mtDNA), mutant (mtDNA-deleted), or CI-inhibited (rotenone-
treated) osteosarcoma 143B cells. This decrease was not detected in
rotenone-treated rho0 cells, proving this to be an effect dependent on
inhibition of functional mitochondria [44]. Tumoral osteosarcoma
143B cells are proliferative and undifferentiated cells. Therefore, OX-
PHOS dysfunction can have different secretory effects on different cell
types.
It was observed that frozen sections of human white adipose tissue
lack of FN1 immunoreactivities, but the same sections showed positive
staining around blood vessels, nerves and mammary glandular tissue.
Thus, the absence of FN1 in the subcutaneous adipose tissue is an im-
portant prerequisite for the maintenance of the normal function and
morphology of the fully differentiated adipocytes [45]. On the other
side, it has also been informed that adipocyte differentiation of mouse
3T3-F442A cells is inhibited by FN1 [46]. Thymidine analog NRTIs
provoke mtDNA depletion and OXPHOS dysfunction. Some patients
receiving this medication can present facial and limb lipoatrophy [11].
OXPHOS dysfunction in these NRTIs-treated patients perhaps avoids
large decreases in FN1 secretion and higher extracellular FN1 levels
would inhibit adipocyte differentiation.
Similar to other reports, we have observed that secreted APOE levels
increase with adipocyte differentiation of hASCs. We have also noted
that OXPHOS xenobiotic LIN tends to moderate this rise. The increase
in the amount of secreted FN1 protein and other adipocyte factors
suggests that LIN has no effect on the general secretion process. This
fact is confirmed by the reduction in the intracellular APOE protein and
mRNA amount.
Other observations also support OXPHOS as a regulatory factor for
APOE expression. Thus, the intracellular free cholesterol content regu-
lated APOE mRNA expression in 3T3-L1 adipocytes [47]. The choles-
terol metabolites oxysterols interact with the liver receptor X (LXR) and
regulate APOE expression in adipose tissue [48]. In 3T3-L1 adipocytes,
PPARγ agonists increased, and tumor necrosis factor alpha (TNFα)
decreased, LXR binding to APOE gene and the APOE secretion [49]. The
TNFα effect was mediated by NF-κB binding to APOE gene [50]. Re-
active oxygen species (ROS) also reduced adipocyte APOE expression
via the NF-κB pathway [51]. Very interestingly, PPARγ agonists induce
adipose mitochondrial biogenesis and increase oxygen consumption in
mouse 3T3-L1 and C3H/10T1/2 cells [52]. 3T3-L1 adipocytes treated
with TNFα decreased mitochondrial biogenesis, mtDNA-encoded gene
expression, oxygen consumption and mitochondrial inner membrane
potential [53]. TNFα also increased ROS levels, because these com-
pound usually increase with OXPHOS dysfunction. Thus, along with the
previous observations, the LIN effect on OXPHOS function might ex-
plain the reduction of cellular and secreted APOE protein amount.
Moreover, we previously observed that ribosomal antibiotics CAM and
LIN tent to increase ROS levels [7]. Therefore, these drugs would also
act through the NF-κB pathway.
We have also found that adipocyte differentiation of hASCs is ac-
companied by an increase in global nDNA methylation. It was pre-
viously reported that inhibiting nDNA methylation in 3T3-L1 pre-
adipocytes, or hMSCs, by 5azadC significantly inhibited adipogenesis
[38–40]. Thus, demethylating and upregulating WNT10A gene ex-
pression, which codes for a key factor to determine the fate of hMSCs,
provoke a decreased PPARγ expression and reduced adipocyte differ-
entiation [39,40]. LIN, inhibiting mitochondrial translation, is able to
affect nDNA methylation and reduce PPARγ mRNA levels. Similarly, it
was reported that rho0 cells showed significant changes in the methy-
lation pattern of a number of genes. These methylation changes were
reversed by the restoration of mtDNA in these cells [54]. Mice har-
boring a dysfunctional POLG, the enzyme involved in mtDNA replica-
tion, displayed altered nDNA methylation [55]. Also, nDNA
Fig. 6. Nuclear DNA methylation and PPARγ expression. A) Global nDNA methylation of
untreated or linezolid-treated adipocyte-differentiated human adipose tissue-derived
stem cells (hASCs). B) PPARγ mRNA levels, normalized using the 18S rRNA, of untreated
or linezolid-treated adipocyte-differentiated hASCs. Dashed line (100%) represents the
mean values for hASCs. The bars indicate the percentage in unexposed or 90 μM linezolid-
exposed adipocyte-differentiated hASCs. Error bars represent the standard deviation. *, P
= 0.015 (versus hASCs). #, P ≤ 0.0148 (versus untreated-adipocyte differentiated
hASCs).
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methylation levels were different in transmitochondrial cell lines (cy-
brids) harboring different mtDNAs [56,57]. As cybrids share the same
nDNA and culture conditions, this result meant that mtDNA genetic
variation altered OXPHOS function and caused retrograde signals that
modified nDNA methylation. Very interestingly, it has been recently
found that cybrids from a particular mtDNA genetic background
showed higher levels of nDNA methylation and APOE transcription than
those from other mtDNA haplogroup [58]. All these results suggest that
OXPHOS function, modifying nDNA, can affect PPARγ expression,
APOE production and adipocyte differentiation.
LIN exposure provokes similar effects on adipocyte secretion to
those caused by knockout APOE gene. Thus, FN1 protein levels were
increased in APOE-/- mice. APOE interrupts a mechanically driven feed-
forward loop that increases the expression of FN1 [59]. Plasma levels of
PAI-1 in APOE-/- mice were significantly higher than that of controls
[60]. Mice with selective suppression of adipose tissue APOE expression
and normal circulating APOE levels had a lower leptin, and a higher
adiponectin, expression [61]. In humans, APOE knockdown hMSC-Tert
adipocytes strongly decreased FABP4 gene expression levels [62]. These
facts suggest that LIN effect on adipokine secretion is APOE mediated.
5. Conclusions
Irrespective of the side effects on other tissues, affecting adipocyte
APOE production and, secondarily, other adipokines, LIN can also
contribute to systemic effects. In fact, it has been reported that selective
suppression of adipose APOE expression impacts systemic metabolic
phenotype and adipose tissue inflammation [61]. These results suggest
that OXPHOS xenobiotics acting on adipocytes alter APOE and adipo-
kine production, thus contributing to their systemic effects.
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